Dyadic International

DYAINasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$36.439 M

$1.00 -1.96%

Close of 7 Aug 2026

Revenue

$3.09M

#3377 by revenue

Earnings

-$7.36M

Loss-making

Shares outstanding

36,438,703

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#133TevogenTVGN$41.5M
#134ElutiaELUT$37.6M
#135Dyadic InternationalDYAI$36.4M
#136Aligos TherapeuticsALGS$34.6M
#137Estrella ImmunopharmaESLA$31.1M

Where these numbers come from

Share counts and financials for Dyadic International are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.